Background {#Sec1}
==========

Endometriosis is a common chronic gynecological disease described as the presence of endometrial glands and stroma located outside the uterine cavity, ovaries, fallopian tubes, and even on the bladder or intestines \[[@CR1], [@CR2]\]. It occurs in approximately 10 % of women or teenage girls at reproductive age. Up to 50 % of patients also suffer from infertility \[[@CR3], [@CR4]\]. Clinical symptoms of endometriosis include several types of pain, such as excessive menstrual pain, pelvic pain with defecation, and chronic pelvic pain \[[@CR5]\]. Epidemiological studies revealed a higher risk for endometriosis patients to develop different types of ovarian cancers \[[@CR6], [@CR7]\]. Molecular pathological analyses have provided strong evidence to support the histological transition from benign endometriosis to ovarian malignancy \[[@CR8], [@CR9]\].

Mucins are high-molecular-weight o-glycoproteins that function as the protective and lubricative layers on epithelial surfaces, such as the respiratory, gastrointestinal, and reproductive tracts \[[@CR10]--[@CR13]\]. Gene expression analyses have indicated that MUC1 \~ 4 are the major mucins constitutively expressed in endometrial epithelium, and their levels can be controlled by the menstrual cycle \[[@CR14], [@CR15]\]. With potent roles in cellular proliferation, MUC1 and MUC4 overexpression has been identified as a tumor marker for endometriotic lesions and certain types of ovarian tumors \[[@CR16], [@CR17]\]. Interestingly, genetic polymorphisms in *MUC2* and *MUC4* were recently reported to be associated with endometriosis development and the related infertility \[[@CR18], [@CR19]\]. Because endometriosis shares several similarities with cancer (e.g., highly mobile and proliferative) these data support that alterations in mucins either at the expression level or within their genetic sequences may have a significant impact on endometrium regulation and development.

In this study, we investigated the association between genetic variations of *MUC17* (A.K.A. *MUC3*) and endometriosis development based on the finding of gene expressing profiling in mucinous ovarian carcinoma (MOC), which likely arises from endometriosis \[[@CR20], [@CR21]\]. In this study, the mucin genes *MUC2*, *MUC3A*, and *MUC17* were found to be upregulated in MOC \[[@CR22]\]. Similar to *MUC4*, *MUC17* encodes a membrane-bound mucin containing two EGF (epidermal growth factor)-like domains and a SEA (sea urchin sperm protein, enterokinase and agrin) domain in the extracellular portion, which can interact with human EGF receptor 2 (EGFR2) on the adjacent cell surface. Thus, the growth signal can be transduced to stimulate cellular proliferation \[[@CR23]\]. Of note, MUC17 overexpression can also be found in colon and pancreatic cancers \[[@CR24]\]. Although several lines of evidence support a potent role of MUC17 in tumor development, its role in endometriosis remains unclear. To investigate the possible link with endometriosis, we studied the association of *MUC17* genetic variants with the ovarian cancer biomarker CA125 and the related infertility.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

One hundred eighty-nine Taiwanese patients who underwent surgery for benign ovarian disease and pathology-proven endometriosis at China Medical University Hospital from 1998 to 2011 were enrolled. These patients were diagnosed with ovarian cysts by ultrasound and confirmed by surgical operation. Symptoms of infertility and CA125 levels were also recorded for each patient during the study. Patients who failed to have pathology-proven endometriosis were excluded from this study. Another 191 healthy women were collected as controls who had regular health checkups at the same hospital. Ultrasound assessment indicated healthy conditions in the abdominal cavities of these controls. Both the controls and patients shared similar age profiles. This study was approved by the Institutional Review Board of China Medical University Hospital. Written informed consent was obtained from patients for scientific research and publication of this study.

Genotyping {#Sec4}
----------

Genomic DNA was extracted from peripheral blood leukocytes according to the manufacturer's protocol (Genomic DNA kit; Qiagen, Valencia, CA, USA). DNA fragments containing the target single-nucleotide polymorphism (SNP) sites were amplified by polymerase chain reaction (PCR) using the *Taqman* SNP Genotyping Assay System from Applied Biosystems, Inc. (Carlsbad, CA, USA). The probe search and design are available from the ABI SNP genotyping databank and are listed in Additional file [1](#MOESM1){ref-type="media"}. The PCR amplification conditions were as follows: 95 °C for 5 minutes, followed by 40 cycles at 95 °C for 10 seconds, 56 °C for 10 seconds and 72 °C for 20 seconds, with one additional cycle at 72 °C for 5 minutes. Genetic variations were detected by reading fluorescence signals of the PCR products. A positive signal indicates a perfect match between the probe and tested DNA, thus identifying the allele type.

Statistical analysis {#Sec5}
--------------------

The allelic and genotypic frequency distributions for five SNP sites in endometriosis patients and controls were performed by *χ*^2^ analysis using *SPSS* software (version 10.0; SPSS Inc. Chicago, IL, USA). Allelic and genotypic frequencies were expressed as percentages of the total number of alleles and genotypes. Odds ratios (ORs) were calculated for the allelic and genotypic frequencies with 95 % confident intervals (95 % CIs). The major (wild-type) allele was used as the reference group. Lewontin\'s D\' (\|D\'\|) and the linkage disequilibrium (LD) coefficient *r*^2^ were determined between selected pairs of biallelic loci. Haploview version 3.2 software (Broad Institute, Cambridge, MA) was used to examine the structure of the LD block.

Prediction of mRNA secondary structures adjacent to the SNP sites {#Sec6}
-----------------------------------------------------------------

The sequence of rs10953316, as well as the reference sequence, were submitted to the RNAstructure web server (<http://rna.urmc.rochester.edu/RNAstructureWeb/index.html>) \[[@CR25]\], and structures with maximum expected accuracy were selected. Among the multiple algorithms in the RNAstructure web server, MaxExpect was utilized to generate structures composed of highly probable base pairs with the highest probability of being accurate.

Immunohistochemistry {#Sec7}
--------------------

A total of 76 ectopic endometrial tissues were collected from patients with different genotypes at the rs10953316 SNP site. Rabbit anti-MUC17 polyclonal antibody (ab122184) was purchased from Abcam PLC., Cambridge, USA. Immunohistochemistry was performed with an antibody dilution of 1:50 using standard protocols with an EnVision + System peroxidase kit (DAKO Agilent Technologies, Glostrup, Denmark). Immunointensity of MUC17 in endometrial epithelium was independently scored by two pathologists and specific membrane staining was labeled as: weak positive, moderately positive, or strongly positive. For discordant cases, a third investigator was brought in to score and the final intensity score was determined by the majority scores.

Results {#Sec8}
=======

*MUC17* polymorphisms and endometriosis {#Sec9}
---------------------------------------

To examine whether SNPs in *MUC17* play a role in endometriosis, five SNPs were selected for this study, with a frequency greater than 5 % in the Chinese Han in Beijing from the International HapMap Project databank. The SNPs locations in *MUC17* are indicated in Fig. [1a](#Fig1){ref-type="fig"}. These SNPs were either located in the open reading frame region or the 3′-untranslated region (3′-UTR) of *MUC17*. The LD values of selected SNPs in patients are shown in Fig. [1B](#Fig1){ref-type="fig"}. Genotype analysis and allele distributions of SNPs in *MUC17* in the patients and controls are analyzed in Table [1](#Tab1){ref-type="table"}. The major (wild-type) alleles were used as the references. Genetic analysis showed a significant association between endometriosis and genetic variation at the SNP site of rs10953316 with a lower frequency of the A allele in patients than in controls (*p* = 0.008; OR = 0.53; 95 % CI: 0.36-0.79) (Table [1](#Tab1){ref-type="table"}). Genotype analysis of the rs10953316 site supported the protective potential of the AG genotype in endometriosis development compared with the reference GG genotype (OR = 0.45; 95 % CI: 0.29-0.7). The AA genotype was not found to show a dominant effect due to the limited sample size. Allelic and genotype analyses of the other SNPs showed no statistically significant differences.Fig. 1Locations of the selected SNPs and their linkage disequilibrium association in the *MUC17* gene in Taiwanese endometriosis patients. (**a**) Genetic alterations of rs4729645, rs10953316 and rs74974199 are located in the coding sequence region, while those of rs4729655 and rs4729656 are located at the 3′ end of the untranslated region in *MUC17*. (**b**) Values are shown with Lewontin's D'Table 1Genotype and allele distributions of SNPs in *MUC17* gene in Taiwanese endometriosis patients and controls*Genotype/alleleNo. (%) of patientsNo. (%) of controlsP-value* ^*a*^*Corrected P-value* ^*b*^*OR95 % CI*rs4729645TT0 (0.0)2 (1.0)0.130.650.00NACT61 (33.0)76 (39.8)0.730.48-1.12CC124 (67.0)113 (59.2)1.00T61 (16.5)80 (20.9)0.120.60.710.47-1.09C309 (83.5)302 (79.1)1.00rs10953316AA1 (0.5)1 (0.5)0.0018\*0.009\*0.770.05-12.65AG45 (23.8)77 (40.5)0.450.29-0.70GG143 (75.7)112 (58.9)1.00A47 (12.3)79 (20.8)0.0016\*0.008\*0.530.36-0.79G335 (87.7)301 (79.2)1.00rs74974199CC3 (1.6)1 (0.5)0.241.22.860.29-28.61CG36 (19.4)48 (25.4)0.710.44-1.17GG14 7 (79.0)140 (74.1)1.00C42 (11.3)50 (13.2)0.422.10.830.54-1.29G330 (88.7)328 (86.8)1.00rs4729655TT27 (14.6)21 (11.1)0.582.901.350.71-2.54CT96 (51.9)104 (54.7)0.970.62-1.51CC62 (33.5)65 (34.2)1.00T150 (40.5)146 (38.4)0.552.751.090.82-1.46C220 (59.5)234 (61.6)1.00rs4729656TT21 (11.3)19 (10.0)0.904.51.170.59-2.34AT82 (44.1)83 (43.7)1.050.68-1.61AA83 (44.6)88 (46.3)1.00T124 (33.3)121 (31.8)0.663.31.070.79-1.45A248 (66.7)259 (68.2)1.00\*Indicates statistical significance^a^P-values were calculated using *χ*2 test^b^P-values were corrected by Bonferroni correction

*MUC17* polymorphisms and infertility {#Sec10}
-------------------------------------

Because endometriosis is considered one of the factors that cause infertility, we next studied the relationship between *MUC17* SNPs and infertility. The endometriosis patients were sub-grouped into the fertile and infertile groups for allele distribution analysis. The results shown in Table [2](#Tab2){ref-type="table"} indicate that the genetic variant rs4729655 is a protective genetic factor for infertility in patients (*p* = 0.0465; OR = 0.42; 95 % CI: 0.21-0.82). The genetic variant at rs4729656 also showed a protective tendency, although this result did not reach statistical significance after Bonferroni correction.Table 2Allele distributions of SNPs in *MUC17* gene *vs.* infertility*PolymorphismInfertileNon-InfertileP-value* ^*a*^*Corrected P-value* ^*b*^*OR95 % CIMAFMAF*rs472964523.113.80.0900.451.830.87-3.82rs109533169.612.20.603.00.840.46-1.53rs7497419913.511.40.683.401.200.49-2.90rs472965525.044.50.0093\*0.0465\*0.420.21-0.82rs472965621.235.40.046\*0.230.480.24-0.98\*Indicates statistical significanceMAF: minor allele frequency^a^P-values were calculated using *χ*2 test^b^P-values were corrected by Bonferroni correctionTable 3Allele distributions of SNPs in *MUC17* gene *vs.* CA-125 level*PolymorphismCA125 ≥ 35* ^*c*^*CA125 \< 35P-value* ^*a*^*Corrected P-value* ^*b*^*OR95 % CIMAFMAF*rs472964515.113.60.763.801.120.61-2.13rs1095331613.012.50.914.551.030.42-2.51rs7497419914.45.70.045\*0.2252.750.99-7.61rs472965564.446.60.0076\*0.038\*2.081.20-3.57rs472965628.844.30.015\*0.0750.490.28-0.87\*Indicates statistical significanceMAF: minor allele frequency^a^P-values were calculated using *χ*2 test^b^P-values were corrected by Bonferroni correction^c^CA125 level: KU/L

*MUC17* polymorphism and CA125 levels {#Sec11}
-------------------------------------

Cancer antigen 125 (CA125), also known as MUC16, is a commonly used serum biomarker to monitor the progress and recurrence of ovarian malignancy and benign conditions, including endometriosis. It has been shown that serum CA125 levels are markedly elevated in women with cystic ovarian endometriosis and/or deeply infiltrating endometriosis compared with women in the luteal phase with minimal or mild endometriosis \[[@CR26]\]. Therefore, we asked whether SNPs in *MUC17* can affect the serum CA125 levels in patients. Patients were sub-grouped into two groups for genetic analyses based on the CA125 level: high CA125 ([≥]{.ul}35 KU/L) and low CA125 (\<35 KU/L) groups \[[@CR27], [@CR28]\]. Our data indicated that patients with the rs4729655 SNP showed a significantly high expression level of CA125 (*p* = 0.038; OR = 0.48; 95 % CI: 0.28-0.83). Genetic variation at rs74974199 also showed a correlation with elevated CA125 expression levels; however, such correlation did not reach statistical significance after Bonferroni correction. By contrast, patients with genetic variation at rs4729656 showed a tendency toward a lower CA125 level (Table [3](#Tab3){ref-type="table"}).

*MUC17* rs10953316 polymorphism controls its protein expression level {#Sec12}
---------------------------------------------------------------------

Based on above findings, the rs10953316 polymorphism was defined as a unique genetic factor regulating endometriosis development. However, this SNP is a silent genetic variation resulting in no amino acid change (Thr2355Thr). Therefore, we asked whether such a SNP can induce an RNA structural conformational change using the MaxExpect algorithm from the RNAstructure web server \[[@CR25]\]. MaxExpect analysis revealed that the mRNA with genetic variation at rs10953316 forms an additional loop adjacent to the SNP site (Fig. [2a](#Fig2){ref-type="fig"}). Because mRNA structural change could be a hindrance to its stability and translation efficiency \[[@CR29]\], we performed immunohistochemistry on endometriosis tissues to see whether such variation can influence the total amount of MUC17. As shown in Fig. [2B](#Fig2){ref-type="fig"}, patients with AA genotype at rs10953316 showed low MUC17 levels in their endometrium, patients with GA genotype showed moderate levels, and strong staining could be found in patients with GG genotype.Fig. 2Influence of rs10953316 SNP on MUC17 mRNA structure and protein expression. (**a**) Partial mRNA structure of wild-type and rs10953316 SNP in *MUC17* were predicted by MaxExpect. Symbol \*indicates the reference allele G and minor allele A sites of the rs10953316 SNP. (**b**) Immunohistochemistry against MUC17 was performed on endometrial tissues in patients. Representative staining results in patients with GG (*left*), AG (*middle*), and AA (*right*) genotypes at rs10953316 SNP site are shown. Specific staining can be detected at the edges of endometrium (arrows)

Discussion {#Sec13}
==========

In this study, we showed molecular evidence that the A allele of rs10953316 in *MUC17* may function as a protective factor in endometriosis development. One of our limitations is the relatively small sample size, so that genotype AA at rs10953316 did not show a stronger effect (OR = 0.77, 95 % CI: 0.05-12.65) than the genotype AG (OR = 0.45; 95 % CI: 0.29-0.7). Although the rs10953316 polymorphism is a silent genetic variation, the total protein amount of MUC17 can be influenced probably due to RNA structural conformational change (Fig. [2](#Fig2){ref-type="fig"}). Our finding supports the previous hypothesis that structural change in RNA coding region can lead to ribosome pause and affect translational efficiency \[[@CR29]\]. Similar finding was also evidenced by Nackley *et al.* that haplotypes divergent in synonymous changes in human *COMT* gene alter the mRNA structure with additional loops and reduced the amount of translated protein, which subsequently affected its function such as pain perception \[[@CR30]\]. Because the extracellular domain of MUC17 protein contains several EGF-like functional domains, reduction of MUC17 expression by rs10953316 SNP may down-regulate the erbB signaling leading to inhibition of cell proliferation \[[@CR23]\]. In addition, SEA domain at the C-terminal region of MUC17 is critical for its autoproteolysis, which controls cell migration and invasion \[[@CR31]\]. These studies provide clues for us to presume that rs10953316 SNP plays a protective role in endometriosis development by reducing total MUC17 expression and the downstream signaling, whereas the detailed mechanism remains to be further investigated.

Another SNP, rs4729655, was linked to endometriosis-related infertility and was associated with abnormally high levels of CA125. The rs4729655 SNP site is located at the 3′-UTR of *MUC17*, a regulatory region for mRNA stability and miRNA binding. We next analyzed whether there was any possible miRNA targets gained or lost due to genetic variation at the rs4729655 SNP site. Our study found that genetic variation at rs4729655 resulted in the gain of miR-4508 and loss of miR-3158-3p toward the 3′-UTR of *MUC17*; thus, this SNP site may be involved in multiple miRNA interactions and gene regulation. Our previous study showed that a miR-125b binding site variation at the 3′-UTR of *BMPR1B* defines endometriosis susceptibility and CA125 levels \[[@CR32]\]. Currently, biofunctions and downstream targets of miR-4508 and miR-3158-3p are still largely unknown. However, studies on the miRNAome of different cancer types using a deep sequencing approach provided solid evidence indicating the involvement of these two miRNAs in cancer development \[[@CR33]--[@CR36]\]. Particularly, miR-3158-3p expression was found to be associated with disease states in the female reproductive tract, including ovarian cancer and endometriosis \[[@CR35]\]. Whether dysregulation of these two miRNAs could lead to infertility remains unclear. Further studies on these two miRNAs may provide insights to uncover the detailed mechanisms regarding how they regulate the development of female reproductive diseases.

One obstacle of this study was that the SNP associated with endometriosis development did not show an influence on infertility or CA125 levels in patients, and *vice versa*. Our data may reflect that more than 50 % of patients with endometriosis-related infertility are diagnosed as having minimal or mild clinical symptoms \[[@CR37]\]. By contrast, the sensitivity and specificity of the CA125 blood test was also found to be limited, not necessary correlating with clinical stages. Therefore, it was recommended as an indication that women with high CA125 levels should receive further diagnostic screening and treatment \[[@CR38], [@CR39]\]. Cytokine/hormone networking, good oocyte quality and the success of embryo implantation may be the key players to determine endometriosis-related infertility. Because mucins have been found to play roles in regulating the immune responses of the reproductive tract and cellular proliferation of endometrial cells, whether MUC17 also plays such a roles is an interesting topic for us to further investigate.

Conclusions {#Sec14}
===========

In this study, we analyzed and found the association between *MUC17* polymorphisms and endometriosis, endometriosis-related infertility and CA125 in a Taiwanese population. However, the relatively small sample size is one limitation of this study, and the conclusions should be further validated by another study cohort. The detailed regulatory mechanisms regarding how MUC17 functions and collaborates with its binding miRNAs in promoting endometriosis development remain to be elucidated.

Additional file {#Sec15}
===============

Additional file 1: Table S1.Probes used for analyzing SNPs in *MUC17* gene. (PDF 108 kb)
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:   cancer antigen 125

MOC

:   mucinous ovarian cancer

SNP

:   single-nucleotide polymorphism
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